Barriers And Facilitators To Clinical Trial Enrollment: A Qualitative Study Of Pancreatic Cancer Patients

May 11, 2026 updated by: M.D. Anderson Cancer Center
The purpose of this research is to understand why some groups of people do not join clinical trials as much as others. These groups can include people from different racial or ethnic backgrounds, people with lower incomes, people who live in rural areas, and people who speak different languages. Investigators interview participants to learn about their experiences with clinical trials. By learning from them, investigators hope to find better ways to help more people learn about, join, and stay in clinical trials so that research is fair and helpful for everyone.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Primary Objectives:

The primary objective of this study is to comprehensively assess the barriers to and facilitators of interventional clinical trial enrollment via in-depth interview of participants with pancreatic cancer among diverse backgrounds. The primary outcome will be identification of specific opportunities for improvement to increase study enrollment.

The above aim is part of a long-term multi-armed quality improvement project with the goal of increasing clinical trial enrollment among minority individuals with pancreas cancer. Using the data gained from this project, investigators aim to implement and tailor interventions towards addressing these barriers in conjunction with current scientific evidence. While the QI project is separate from this IRB submission, data gained from this specific research study will be crucial towards steering further improvement efforts.

Study Type

Observational

Enrollment (Estimated)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • UT MD Anderson
        • Contact:
        • Principal Investigator:
          • Rebecca A Snyder, MD, MPH

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

UT MD Anderson

Description

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Males and females; Age ≥18
  • Documented diagnosis of pancreatic cancer
  • Access to necessary resources for participating in a technology-based intervention (i.e., computer, smartphone, internet access)

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Patients who speak a primary language other than English or Spanish
  • Patients who are cognitively impaired
  • Pregnant women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
All patients
Participants will be sampled using pre-selected demographic, geographic, and clinical characteristics, allowing for purposive sampling among patients with characteristics where disparities are known to exist.
Other: Interviews
Participants will be offered a 30 to 45-minute telephone or video in-depth interview at a specific time convenient to the participants.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Questionnaires/Surveys
Time Frame: Through study completion; an average of 1 year
Identification of specific opportunities for improvement to increase study enrollment.
Through study completion; an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Rebecca A Snyder, MD, MPH, UT MD Anderson

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

October 1, 2028

Study Registration Dates

First Submitted

April 8, 2026

First Submitted That Met QC Criteria

May 11, 2026

First Posted (Actual)

May 15, 2026

Study Record Updates

Last Update Posted (Actual)

May 15, 2026

Last Update Submitted That Met QC Criteria

May 11, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2026-0019
  • NCI-2026-02708 (Other Identifier: NCI-CTRP Clinical Trials Registry)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe